The investigators will perform a study with 25 patients in whom the investigators have a
strong suspicion of prostate cancer that has returned to the body after having an initial
treatment. The major goal of the investigation is to see whether anti-[18F] FACBC PET-CT and
MRI imaging individually will be useful in the detection of local and extraprostatic
recurrence of prostate cancer. Routine blood test will be done on the day of the FACBC scan
and one week later as required by the FDA. All patients will undergo biopsy of the prostate
as clinically appropriate per standard of care. If either the FACBC or MRI scans indicate
cancer recurrence, the subject's cancer site(s) will also be biopsied as clinically
appropriate.